# The Genetics Company

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/the-genetics-company

- Industry: Biotechnology
- Headquarters: Basel, Switzerland
- Website: www.the-genetics.com
- Total disclosed funding: $34M
- Latest round: Series C (Jun 1, 2007)
- Investors on record: 6

## About

The Genetics Company Inc. focuses on biopharmaceutical innovation to diagnose, monitor, and treat neurodegenerative diseases and various cancers, particularly through small molecule therapeutics targeting critical biological pathways.The Genetics Company Inc. specializes in developing biopharmaceutical products targeting neurodegenerative diseases and cancers. The company is headquartered in Basel, Switzerland. In 2007, it raised CHF 8 million in the Second tranche of Series C funding, co-led by Nextech Invest and Novartis Venture Funds with support from Varuma AG. The company has completed 7 deals since its inception.The Genetics Company specializes in the research, development, and commercialization of innovative biopharmaceutical products aimed at diagnosing, monitoring, and treating neurodegenerative diseases such as Alzheimer's disease and various forms of cancer, notably colorectal cancer. Key offerings include small molecule Wnt-inhibitors designed to target the aberrant Wnt signaling pathway in colorectal cancer, small molecule BACE inhibitors that inhibit the ß-site amyloid precursor protein cleaving enzyme 1 (BACE1) for Alzheimer's treatment, and a range of small molecule inhibitors that regulate cellular growth in cancer therapy. These products aim to address critical unmet medical needs, specifically targeting the underlying biological mechanisms that contribute to disease progression. The company's customer base includes healthcare providers, research institutions, and pharmaceutical partners across North America, Europe, and Asia.The Genetics Company generates revenue through the sale of its specialized therapeutics and partnerships with healthcare institutions and pharmaceutical companies. Transactions typically occur through B2B partnerships where healthcare providers and pharmaceutical companies acquire therapeutic products for clinical applications. The company may offer tiered pricing plans for its small molecule therapeutics, structured to accommodate bulk purchases by hospitals and research facilities, promoting accessibility and uptake in diverse healthcare settings. Specific pricing details for individual products are strategically aligned with market demands and the unique value proposition of their therapeutics, particularly their flagship small molecule inhibitors that address critical pathways in neurodegenerative diseases and cancer.In the future, The Genetics Company plans to launch new products focused on expanding its range of therapeutics for neurodegenerative diseases and cancers. The recent CHF 8 million raised in June 2007 from the Second tranche of Series C funding will be utilized to support these new product developments and enhance their research capabilities. The company is also targeting expansion into Asian markets by 2025, aiming to increase accessibility of its innovative therapeutics in underserved regions.

## Funding rounds

- Series C, Jun 1, 2007, $6.5M — Novartis Venture Fund, Nextech, Varuma
- Series C, Feb 15, 2005, $15M — Novartis Venture Fund, Nextech, Varuma
- Series B, Nov 14, 2003, $6.4M — Heidelberg Innovation Funds Management, Novartis Venture Fund, Nextech, Najeti Group
- Series A, Jul 1, 2000, $3.7M — Nextech
- Series A, May 1, 2000, $2.7M — Novartis Venture Fund, BPP Business Promotion Partners

## Investors

- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A, Series B, Series C
- BPP Business Promotion Partners — Series A
- Nextech (https://capitalatlas.ai/funds/nextech) — Series A, Series B, Series C
- Heidelberg Innovation Funds Management (https://capitalatlas.ai/funds/heidelberg-innovation-funds-management) — Series B
- Najeti Group (https://capitalatlas.ai/funds/najeti-group) — Series B
- Varuma — Series C